C23G10.1 Antibody

What is C23G10.1 Antibody and what does it target?

C23G10.1 Antibody is a research reagent that specifically targets the C23G10.1 protein, which functions as a putative serine/threonine-protein phosphatase. This antibody is designed for detection and study of this phosphatase in experimental systems. When selecting this antibody, researchers should first verify target expression in their experimental system through RNA expression databases or preliminary screening. Antibody specificity should be confirmed through validation methods such as immunoprecipitation followed by mass spectrometry (IP-MS) to ensure accurate target binding and experimental reliability. For optimal results, researchers should evaluate antibody performance in their specific experimental conditions before proceeding with larger studies.

How should I validate C23G10.1 Antibody specificity for my experiments?

Validation of C23G10.1 Antibody should follow the comprehensive strategy recommended by the International Working Group on Antibody Validation (IWGAV) . First, employ genetic strategies using CRISPR-Cas or RNAi to create knockout or knockdown cell models of C23G10.1, then test antibody reactivity against these and wild-type controls. Second, use orthogonal strategies by comparing antibody detection with an antibody-independent quantitation method like mass spectrometry. Third, utilize independent antibody strategies by testing multiple antibodies targeting different epitopes of C23G10.1. This multi-pillar approach ensures confidence in antibody specificity and reduces the risk of experimental artifacts or misinterpretation of results due to off-target binding.

What controls should I include when using C23G10.1 Antibody in my experiments?

For rigorous experimental design with C23G10.1 Antibody, implement the following control system:

What are the optimal conditions for using C23G10.1 Antibody in Western blotting?

For optimal Western blot results with C23G10.1 Antibody, begin with sample preparation using a phosphatase inhibitor-supplemented lysis buffer (particularly important since the target is a putative phosphatase). Use 20-40 μg of total protein per lane, separated on a 10-12% SDS-PAGE gel. Following transfer to a PVDF membrane, block with 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature. Incubate with C23G10.1 Antibody at a 1:500-1:1000 dilution (starting point for optimization) overnight at 4°C. Perform at least three 10-minute TBST washes, then incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature. After additional washing, develop using enhanced chemiluminescence. Always include positive and negative controls, and perform preliminary titration experiments to determine optimal antibody concentration for your specific sample type .

How can I effectively use C23G10.1 Antibody for immunoprecipitation studies?

For successful immunoprecipitation (IP) with C23G10.1 Antibody, begin with well-validated antibody as confirmed by Western blotting. Use MS-Compatible Magnetic IP kits with protein A/G beads for maximum compatibility . Prepare cell lysates in non-denaturing buffer containing protease/phosphatase inhibitors (crucial for phosphatase targets). Pre-clear lysate with protein A/G beads for 1 hour at 4°C before adding 2-5 μg of C23G10.1 Antibody to 500-1000 μg of lysate. Incubate overnight at 4°C with gentle rotation. Capture antibody-protein complexes with fresh protein A/G beads for 1-2 hours, then wash 4-5 times with cold IP buffer. Elute using gentle conditions (non-reducing, low pH) if planning subsequent functional assays, or more stringent conditions (reducing, SDS-containing) for analysis by Western blot or mass spectrometry. Always include an isotype control antibody IP and perform validation by mass spectrometry to confirm target enrichment and identify interaction partners .

What sample preparation methods are critical for immunofluorescence with C23G10.1 Antibody?

For immunofluorescence with C23G10.1 Antibody, sample preparation is critical to preserving phosphatase epitope accessibility while maintaining cellular architecture. Fix cells using 4% paraformaldehyde for 15 minutes at room temperature, avoiding methanol fixation which can disrupt phospho-epitopes. For membrane permeabilization, use 0.1-0.2% Triton X-100 for 10 minutes, as excessive permeabilization can reduce signal intensity. When blocking, use 5% normal serum from the same species as the secondary antibody in PBS with 0.1% Tween-20 for 1 hour. For primary antibody incubation, dilute C23G10.1 Antibody 1:100-1:200 in blocking buffer and incubate overnight at 4°C. Include phosphatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovanadate) in all buffers to preserve phosphorylation states. Validate staining pattern using known subcellular markers and compare with RNA expression data to confirm specificity of observed localization patterns .

How can I use C23G10.1 Antibody to study protein-protein interactions in signaling pathways?

To study protein-protein interactions involving C23G10.1 phosphatase, implement a multi-method approach centered on immunoprecipitation followed by mass spectrometry (IP-MS) . Begin with standard IP using C23G10.1 Antibody as described in FAQ 2.2, then analyze immunoprecipitated complexes via nanoLC-MS/MS. Process data through Proteome Discoverer or MaxQuant software, filtering out common background proteins and submitting enriched proteins to STRING database analysis for interaction network mapping . Validate key interactions through reciprocal co-IP experiments and proximity ligation assays (PLA). For dynamic interaction studies, perform IPs under various stimulation conditions to capture context-dependent interactions. Compare results with orthogonal methods such as BioID or APEX proximity labeling to build confidence in identified interactions. This comprehensive approach allows mapping of C23G10.1's role in signaling networks while minimizing false positives inherent to individual interaction detection methods.

What approaches can resolve contradictory results when using C23G10.1 Antibody across different experimental systems?

When facing contradictory results with C23G10.1 Antibody across different experimental systems, implement a systematic troubleshooting strategy. First, perform comprehensive antibody validation using multiple methods as described in FAQ 1.2, including genetic strategies (knockout/knockdown), orthogonal methods, and independent antibodies targeting different epitopes . Second, normalize experimental conditions by standardizing sample preparation protocols, antibody concentrations, and detection systems across platforms. Third, consider biological variables that might explain discrepancies, such as tissue-specific post-translational modifications, alternative splicing, or interaction partners that might mask epitopes. Fourth, implement quantitative approaches like multiple reaction monitoring mass spectrometry to provide antibody-independent measurement of target levels. Finally, collaborate with experts using different systems to perform blinded cross-laboratory validation. Document all experimental conditions meticulously to identify variables contributing to discrepancies and establish a consensus protocol that yields reproducible results across systems.

How can I integrate C23G10.1 Antibody-based approaches with phosphoproteomics to study enzymatic function?

To integrate C23G10.1 Antibody-based approaches with phosphoproteomics, develop a workflow that leverages both antibody specificity and the unbiased nature of mass spectrometry. Begin by using C23G10.1 Antibody for immunoprecipitation to isolate the phosphatase and its complexes. Process these samples for both standard proteomics (to identify interactors) and phosphopeptide enrichment (to identify phosphorylation states) . In parallel, perform phosphoproteomic analysis on samples where C23G10.1 is overexpressed, knocked down, or inhibited to identify substrates. To establish direct enzymatic relationships, implement in vitro phosphatase assays using immunopurified C23G10.1 and candidate substrates. Validate findings using site-specific phospho-antibodies against putative substrate sites. This integrated approach allows mapping of both the interactome and substrate-enzyme relationships of C23G10.1, providing mechanistic insight into its cellular functions.

What specific modifications to IP-MS protocols are needed when studying phosphatase activity of C23G10.1?

When studying C23G10.1 phosphatase activity via IP-MS, specific protocol modifications are essential to preserve enzymatic function and capture transient substrate interactions. First, modify lysis buffers to include phosphatase inhibitor cocktails excluding those that might inhibit C23G10.1's specific catalytic mechanism; this preserves substrate phosphorylation states while allowing isolation of active C23G10.1. Second, implement substrate-trapping approaches by using phospho-dead mutants (e.g., C23G10.1 with catalytic site mutations) that bind but cannot dephosphorylate substrates, extending the duration of enzyme-substrate interactions. Third, perform crosslinking before lysis using membrane-permeable crosslinkers like DSP (dithiobis(succinimidyl propionate)) at optimized concentrations to capture transient interactions. Fourth, incorporate SILAC or TMT labeling to quantitatively compare substrate phosphorylation levels between wild-type and C23G10.1-deficient samples. Finally, analyze data with specialized phosphoproteomic workflows that consider both protein abundance changes and phosphorylation site stoichiometry to distinguish direct substrates from downstream effects .

How can I optimize multiplex immunofluorescence to study C23G10.1 colocalization with other signaling components?

For multiplex immunofluorescence studying C23G10.1 colocalization, implement a strategic optimization approach. First, select antibodies with complementary host species to C23G10.1 Antibody, enabling simultaneous detection without cross-reactivity. If using multiple mouse-derived antibodies, implement tyramide signal amplification (TSA) or sequential staining with antibody stripping between rounds. Second, validate antibody performance individually before combining, confirming specificity and optimal working dilutions. Third, optimize fluorophore selection to minimize spectral overlap; consider using spectral unmixing algorithms for closely overlapping fluorophores. Fourth, implement quantitative colocalization analysis using Pearson's correlation coefficient or Manders' overlap coefficient rather than relying on visual assessment alone. Fifth, use super-resolution techniques like STED or STORM for examining nanoscale colocalization that might be missed by conventional confocal microscopy. Always include appropriate controls, including single-stained samples for establishing compensation matrices and knockout/knockdown controls for validating antibody specificity in the multiplexed context .

What considerations are important when using C23G10.1 Antibody for studying degradation and turnover of the phosphatase?

When studying C23G10.1 phosphatase degradation and turnover, several technical considerations are critical. First, select antibody formats carefully; use unconjugated C23G10.1 Antibody for pulse-chase experiments and fluorescently conjugated versions for live-cell imaging of turnover dynamics. Second, validate that the antibody epitope remains accessible during degradation processes by comparing detection of various degradation intermediates. Third, implement cycloheximide chase assays with carefully optimized time points based on preliminary half-life experiments. Fourth, combine antibody-based detection with orthogonal approaches such as SNAP/CLIP-tagging or global proteomics with stable isotope labeling to independently verify turnover rates. Fifth, consider compartment-specific degradation by performing subcellular fractionation before antibody-based detection. Finally, evaluate the impact of post-translational modifications on antibody binding affinity, as phosphorylation or ubiquitination might alter epitope accessibility during the degradation process. These considerations ensure accurate measurement of C23G10.1 turnover dynamics without artifacts introduced by the detection method itself .

How can C23G10.1 Antibody be utilized in single-cell analysis techniques?

For applying C23G10.1 Antibody in single-cell analysis, implement specialized protocols adapted for low-input samples. For single-cell Western blotting, use microfluidic platforms with optimized antibody concentrations (typically 5-10× higher than conventional Westerns) and extended incubation times to compensate for reduced target abundance. For mass cytometry (CyTOF), conjugate C23G10.1 Antibody with rare earth metals using commercial conjugation kits, carefully titrating to determine optimal signal-to-noise ratio in control samples. For single-cell imaging applications, employ signal amplification methods such as tyramide signal amplification or proximity ligation assay to detect low-abundance phosphatase. When developing custom protocols, validate antibody performance at the single-cell level by comparing results with bulk measurements and using cells with known expression levels as controls. This approach enables investigation of cell-to-cell heterogeneity in C23G10.1 expression and phosphatase activity that would be masked in population-level analyses .

What methodological approaches can integrate C23G10.1 Antibody use with CRISPR-based gene editing for functional studies?

To integrate C23G10.1 Antibody with CRISPR-based functional studies, implement a systematic workflow combining genetic manipulation with immunodetection. Begin by designing CRISPR-Cas9 strategies targeting C23G10.1, including complete knockout, catalytic domain mutations, and epitope tagging approaches. For knockout validation, use C23G10.1 Antibody to confirm protein depletion by Western blot and immunofluorescence, comparing with wild-type controls . For structure-function studies, create domain-specific mutations or truncations and use the antibody to verify expression levels before phenotypic assessment. For mechanistic investigations, implement CRISPR activation (CRISPRa) or interference (CRISPRi) to modulate C23G10.1 expression levels, using the antibody for quantitative assessment of dosage effects. When introducing epitope tags via CRISPR knock-in, compare detection between endogenous antibody and tag-specific antibodies to ensure tag incorporation doesn't disrupt normal localization or function. This integrated approach combines the specificity of genetic manipulation with the detection capabilities of antibody-based methods to comprehensively characterize C23G10.1 function.

How can researchers interpret C23G10.1 Antibody data in the context of contradictory phosphoproteomic findings?

When integrating C23G10.1 Antibody data with potentially contradictory phosphoproteomic findings, implement a structured analytical framework. First, evaluate methodological differences including sample preparation protocols, enrichment strategies, mass spectrometry platforms, and data analysis pipelines that might explain discrepancies. Second, examine substrate specificity by determining whether contradictions involve direct enzymatic targets versus downstream signaling effects by performing in vitro phosphatase assays with recombinant C23G10.1 and candidate substrates. Third, consider context-dependency by evaluating whether contradictions arise from different cellular conditions, stimulation states, or tissue types. Fourth, implement targeted phosphoproteomics using parallel reaction monitoring (PRM) to specifically quantify phosphosites of interest with higher sensitivity than discovery-mode proteomics. Fifth, develop an integrated computational model incorporating data from both antibody-based and MS-based approaches, weighting evidence based on methodological robustness. This systematic approach transforms apparent contradictions into opportunities for deeper mechanistic understanding of C23G10.1's complex regulatory roles in phosphorylation networks .